Steffen Wagner has taken over as Stada’s head of Germany, adding to his existing responsibilities in Europe, after Eelco Ockers stepped down from the role. Ockers’ departure comes as German generics giant Stada restructures its business to bring its branded and consumer health interests into closer alignment as part of a more streamlined model.

Hikma has named Patrick Genestin as its new head of business development for generics, bringing to the role 25 years of experience that includes most recently a 15-year stint at Sandoz. In turn, Sandoz has looked to Teva for a successor.

For the second time in as many months, Neuraxpharm has looked to Viatris to recruit a top executive to help lead the CNS specialist’s continuing expansion in Europe.

The US Association for Accessible Medicines hires for three key leadership roles, while Australia’s Generic and Biosimilar Medicines Association has named Fresenius Kabi’s director in Australia as its newest board member. Coherus’ vice president of market access and government affairs, Thomas Nusbickel, joins CorMedix as chief commercial officer, while other major firms make board changes.

Sandoz has recruited Teva’s Karan Ambwani to head up the Novartis unit’s strategy, business development and portfolio in Europe. Meanwhile, Diane DiGangi Trench is moving from Sandoz US to head up the company’s operations in the UK.

Eden Biologics adds Henlius’ Scott Liu to its board of directors, as  both King & Spalding and Gedeon Richter also make fresh appointments. And Stada has extended the tenure of CEO Peter Goldschmidt.